N-(1-Allyl-2-pyrrolidinyl-methyl) 2-methoxy-4-amino-5-methylsulfamoyl benzamide

ABSTRACT

N-(1-allyl-2-pyrrolidinyl-methyl) 2-methoxy-4-amino-5-methylsulfamoyl benzamide and derivatives thereof, which are useful in the treatment of anomalies in cerebral hemodynamics of patients subject to migraines.

This application is a continuation of application Ser. No. 296,164 filedAug. 25, 1981, now issued as U.S. Pat. No. 4,405,636.

The invention concerns a new benzamide, namely N-(1allyl-2-pyrrolidinyl-methyl)2-methoxy-4-amino-5-methylsulfamoylbenzamide, a method of preparing it and its use as a medicament,particularly for basic migraine treatment.N-(1-allyl-2-pyrrolidinyl-methyl)2-methoxy-4-amino-5-methylsulfamoylbenzamide will hereinafter be referred to as the benzamide according tothe invention; it has the following formula: ##STR1## The inventioncovers the said benzamide according to the invention, quaternaryammonium salts of the benzamide according to the invention, N-oxidesthereof, optical isomers thereof and their pharmacologically acceptableacid addition salts.

A method of obtaining the benzamide according to the invention will nowbe described; the starting material is methyl 2-methoxy-4-acetaminobenzoate which is known in other contexts.

1. Methyl 2-methoxy-4-acetamino-5-sulfo-benzoate ##STR2## Forty-fiveliters of acetic acid is placed in a 100 liter reactor. It is agitatedand 22.5 kg of methyl 2-methoxy-4-acetamino benzoate is added, afterwhich 30 liters of acetic anhydride is fed in. 5,730 liters of sulfuricacid (d:1.84) is added over 15 minutes. The temperature risesspontaneously to 50°. The ester dissolves. The temperature is broughtgradually to 70°. The sulfonic acid crystallises; when 70° C. isreached, the medium is immediately cooled to 20° C. and drained in acentrifugal drier.

The product is washed twice, each time with 8 liters of acetone, thendried in an oven at 50° C.

Properties of product obtained:

Weight: 24.5 kg.

N %: 81.5%.

Melting point: 240° C. with decomposition.

S %: (theory: 10.57%) 10.56%.

White crystals.

2. Methyl 2-methoxy-4-amino-5-sulfo-benzoate ##STR3## 75 liters ofmethanol is placed in a 100 liter reactor. It is agitated and 24.5 kg offinely ground methyl 2-methoxy-4-acetamino-5-sulfobenzoate is added. Thesulfonic acid dissolves; the deacetylated derivative crystallisesshortly afterwards. The reaction mixture is left at room temperature for24 hours, with agitation, so as to complete precipitation. The productis drained in a centrifugal drier, washed twice, with 6 liters of methylalcohol each time, and dried in a ventilated oven at 50° C.; it has thefollowing properties:

Weight: 20.5 kg-Yield 98%.

Melting point: 240° with decomposition.

S %: 12.10%-Theory 12.26%.

3. Methyl 2-methoxy-4-amino-5-methylsulfamoyl benzoate ##STR4##

(a) 33.5 liters of acetonitrile is placed in a 100 liter reactor. It isagitated, and 16.8 kg of methyl 2-methoxy-4-amino-5-sulfobenzoate isadded; 17.5 kg of phosphorus pentachloride is also added in stages, overapproximately 15 minutes. The medium is gradually heated to a refluxtemperature of about 80°-85° C. The reaction starts at about 30°, andthe liberation of a large amount of gas is noted at this time. In twohours the temperature reaches 80°. The reflux is maintained for 1 hour30 minutes. The solution is cooled to 55° C.

(b) 95 liters of an aqueous solution containing 35% of methylamine isplaced in a 200 liter reactor. It is agitated and cooled to -15° C. Theprevious solution (sulfochloride) is then poured in slowly and instages, and the temperature is kept below 10°-15° C. The addition of thesolution takes 4 hours, after which the temperature is allowed to riseto 20°. The solution is diluted with 300 liters of water, then filteredthrough 2 kg of vegetable black. The filtrate is acidified by agitatingit with 70 liters of hydrochloric acid (d=1.18). The product graduallycrystallises. It is left to stand for 120 hours. It is drained, washedwith water and dried in an oven at 50°. 15 kg of the product is therebyobtained.

4. 2-methoxy-4-amino-5-methyl-sulfamoyl benzoic acid ##STR5##

22 liters of water and 22 liters of caustic soda solution are placed ina 100 liter reactor, and 15 kg of the previous product is stirred in.The medium is brought to complete reflux for 20 hours. The liberation ofa large amount of methylamine is observed during the first few hours ofthe reaction. The medium is cooled to 20° C., and the solution is pouredinto the precipitation tank. 12 liters of water is added. The solutionis agitated and acidified to pH 1 with 17 liters of hydrochloric acid(d=1.18). It is necessary to cool the solution while the acid is beingpoured in. The acid crystallises; it is drained at 20°, washed withwater and dried in an oven at 60° C. It has the following properties:

Weight: 12.100 kg.

Melting point: 205° C.

AI: theory 215.4-obtained 212.

S %: theory 12.31%-obtained 12.23%.

40 liters of water and 2.600 kg of sodium bicarbonate are placed in theprecipitation tank. They are agitated, and 12.100 kg of2-methoxy-4-amino-5-methyl-sulfamoyl benzoic acid is added in stages.The acid is dissolved with a great deal of lathering. A small quantityof insoluble gelatinous substance is left, which is removed byfiltration under vacuum. The filtrate is acidified with 5.6 liters ofhydrochloric acid.

The product crystallises; it is drained, washed with water and dried inan oven at 60° C. The properties of the purified acid are then:

Weight: 11.9 kg.

Melting point: 202° C.

AI: theory 215.4-obtained 215.

S %: theory 12.31%-obtained 12.37%.

5. N(1-allyl-2-pyrrolidinyl-methyl)2-methoxy-4-amino-5-methyl-sulfamoylbenzamide ##STR6##

Ten liters of permuted water is placed in a 100 liter reactor. It isagitated, and 5,300 cm³ of triethylamine and 10 kg of2-methoxy-4-amino-5-methyl-sulfamoyl benzoic acid are fed in. Thesuspension is heated to about 45° C. to dissolve everything, after whichit is cooled to +5° C. by a stream of brine, and 25 liters of acetone isadded.

3,670 cm³ of ethyl chloroformate is poured in slowly, (taking 15minutes) without exceeding a temperature of +10° C. Agitation iscontinued for 30 minutes at this temperature. 6.4 kg ofN-allyl-2-aminomethyl pyrrolidine is poured in slowly (taking 30minutes) without exceeding +15° C.

The temperature is allowed to rise to 20°, and the medium is agitatedfor 1 hour at that temperature. The acetone is distilled at normaltemperature then under vacuum, without exceeding 60° C. in the mass.

55 liters of water is added, the medium is acidified to pH 3-4 with 7liters of chemically pure hydrochloric acid, and 1 kg of active carbonblack 3S is added. The solution is filtered. The filtrate is madealkaline with 5 liters of ammonia, with vigorous agitation. 10 kg of iceis added, and the agitation is continued for 1 hour. The benzamide firstcrystallises in liquid form. It is left to stand overnight.

The benzamide is drained at 20°, washed with water and dried in an ovenat 60° C. It has the following properties:

Weight: 9 kg.

Yield: 61%.

Melting point: 166°-167° C.

Using a 50 liter reactor, 9 kg of the benzamide previously obtained isdissolved, boiling, in 18 liters of absolute ethyl alcohol. The solutionis filtered with 1 kg of vegetable black in a pressure filter. Thefiltrate is washed with 2 liters of boiling alcohol, then cooled to 10°.The benzamide crystallises. It is drained, washed with cold alcohol anddried in an oven at 60°. It has the following properties:

White crystals. Weight: 8 kg.

Recrystallisation yield: 89%.

Since chromatographic investigation reveals large spots, it will benecessary to carry out two fresh recrystallisations in absolute ethylalcohol, as a means of arriving at the purified product with thefollowing properties:

White crystals. Weight: 6 kg.

Yield resulting from recrystallisations: 67%.

The process just described produces the benzamide according to theinvention with a total yield of 41%. Analysis of the benzamide thusobtained gives the following results:

Melting point: 168.5°-169° C.

Titre: 99.8% % H₂ O: 0.1.

%C: theory 53.38-obtained: 53.13.

%H: theory 6.85-obtained: 6.88.

%N: theory 14.65-obtained: 14.65.

%S: theory 8.58-obtained: 8.54.

Taken as a unit, the spectra are compatible with the proposed structure.

Chromatographic investigation reveals the existence of a secondary spotestimated to be from 0.2 to 0.5%.

A pharmacological study has been made of the benzamide according to theinvention.

The acute toxicity of the compound was first determined; values forlethal dose 50 with various forms of administration are given below:

    ______________________________________                                        Substance                                                                              Administration                                                                            LD.sub.50 male mouse mg/kg (basis)                       ______________________________________                                        Benzamide                                                                              Intravenous  44                                                      According                                                                              Intra-      184                                                      to the   peritoneal                                                           invention                                                                              Subcutaneous                                                                              204                                                               Per os      3600                                                     ______________________________________                                    

The researchers were looking for the effects of the benzamide on thecentral nervous system and particularly for any neuroleptic action.Tests showed the compound to have very little depressive action, thus:

it only very slightly reduces the spontaneous motility of the mouse,even in high doses (Table 1)

it does not extend the duration of barbituric hypnosis (Table 2).

                  TABLE 1                                                         ______________________________________                                                   Spontaneous motility of mouse:                                                inhibiting effect observed at                                                 maximum dose administered                                                  Adminis- WINTER &       Activograph                                   Product tration  FLATAKER method                                                                              method                                        ______________________________________                                        Benzamide                                                                             I.P.     26% effect at  22% at 80 mg/kg                               according        80 mg/kg                                                     to the  P.O.     20% effect at  25% at 300 mg/kg                              invention        300 mg/kg                                                    ______________________________________                                    

                  TABLE 2                                                         ______________________________________                                                 Adminis- Dose    Time of hypnosis, mice treated                      Product  tration  mg/kg   Time of hypnosis, control mice                      ______________________________________                                        Benzamide                                                                              I.P.     80      1.6                                                 according                                                                     to the                                                                        invention                                                                     ______________________________________                                         N.B. The barbiturate used is pentobarbital in a dose of 60 mg/kg given        intraperitoneally.                                                       

Unlike conventional neuroleptics, the compound does not cause catalepsyin the rat, even in a dose of 200 mg/kg given subcutaneously, and doesnot counteract the stereotypic movements of the rat caused bydopaminergic agonistes, such as apomorphine or amphetamine.

The benzamide has no anticonvulsive action when the convulsions arecaused by electric shock, a chemical agent (pentetrazol, nicotine) or anauditory stimulus.

The analgesic action of the benzamide, in a single dose, is weak inrespect of the pain caused in a mouse by a mechanical, chemical or heatstimulus.

The effects of the benzamide on the cardiovascular system were studiedin a dog anaesthetised with chloralose, with the following results:

The compound causes a drop in arterial pressure proportional to the doseadministered (Table 3)

The compound does not change the hypotensive response to acetylcholineor to excitation of the vagus nerve. The fact that the benzamide has noanticholinergic action was confirmed by a test in vitro on the isolatedileum of a guinea pig.

The compound reduces the hypertensive responses caused by catecholamines(adrenalin and noradrenalin), by blocking the carotid arteries and bysmall doses of nicotine (Table 4)

The compound reduces the hypertensive response to serotonin in a dog,the dog being anaesthetised and further treated with a ganglioplegic,chlorisondamine, which stabilises the response (Table 5)

    ______________________________________                                        Cumulative dose of                                                            benzamide according                                                           to the invention                                                                             Variations in arterial pressure                                (mg/kg/I.V.)   relative to initial pressure                                   ______________________________________                                        0.5            -21%                                                           1              -32%                                                           2              -36%                                                           4              -48%                                                           8              -54%                                                           16             -59%                                                           32             -58%                                                           ______________________________________                                    

                  TABLE 4                                                         ______________________________________                                                       Cumulative dose of                                                            benzamide according                                                           to the invention                                               Methods        (mg/kg/I.V.)                                                   ______________________________________                                        Orthosympathetic system                                                       Blocking of carotid                                                                          0.5             0%                                             arteries       1               R = 30%                                        (for 30 seconds)                                                                             2               R = 43%                                                       4               R = 48%                                        % reduction relative                                                                         8               R = 86%                                        to control hyper-                                                                            16              R = 90%                                        tension (R)    32              R = 100%                                       Adrenalin      0.5             R = 5%                                         % reduction relative                                                                         1               R = 3%                                         to control hyper-                                                                            2               R = 4%                                         tension (R)    4               R = 21%                                                       8               R = 40%                                                       16              R = 68%                                                       32              R = 84%                                        Noradrenalin   0.5             R = 21%                                        % reduction relative                                                                         1               R = 13%                                        to control hyper-                                                                            2               R = 30%                                        tension (R)    4               R = 30%                                                       8               R = 40%                                                       16              R = 49%                                                       32              R = 66%                                        Nicotine       0.5             0%                                             % reduction of ortho                                                                         1               0%                                             sympathetic    2               0%                                             component (R)  4                0%                                                           8               0%                                                            16              R = 49%                                                       32              R = 79%                                        ______________________________________                                    

                                      TABLE 5                                     __________________________________________________________________________           Doses in                                                                           Serotonin                                                                mg/kg                                                                              in μg/kg                                                                        % inhibition of hypertension after                           Product                                                                              I.V. I.V. 3 mn                                                                             30 mn                                                                             1 h                                                                              1 h 30                                                                            2 h                                                                              3 h                                         __________________________________________________________________________    Benzamide                                                                            5    25   62%                                                                              63% 51%                                                                              51% 40%                                                                              --                                          according                                                                            1    37.5 22%                                                                               8% -- --  -- --                                          to the                                                                        invention                                                                     BATCH 1                                                                       Benzamide                                                                            5    25   78%                                                                              65% 48%                                                                              43% 33%                                                                              33%                                         according                                                                            1    25   36%                                                                              11% 0  --  -- --                                          to the                                                                        invention                                                                     BATCH 2                                                                       __________________________________________________________________________

Since the results set out in Table 5 above showed the benzamideaccording to the invention counteracting the pressing effect ofserotonin, search was made for other interactions with serotonin.

Tests showed that the benzamide according to the invention:

inhibited contraction of the isolated uterus of a rat, produced byserotonin. The contraction inhibiting dose 50 is of the order of 0.2mg/l.

had a protective action in respect of the gastric ulcer producing effectof serotonin in the rat, the effective dose 50 being of the order of 3mg/kg given subcutaneously.

reduced the oedema in the paw of a rat which had received anintraplantar injection of 0.01 mg of serotonin. The effective dose 50 isof the order of 4 to 6 mg/kg when administered by intraplantar injectionand 200 mg when given orally.

Finally, researchers looked for interaction between the benzamideaccording to the invention and histamine, in the arterial pressure of ananaesthetised dog and the isolated ileum of a guinea pig. Noanti-histamine properties were revealed by the two tests.

Given the pharmacological profile of the benzamide according to theinvention, as defined by the tests reported above, it became apparentthat the antiserotonin action component on the one hand and thecirculatory effect on the other might give the benzamide a therapeuticimportance in migraines, which is precisely the area where vasomotordisorders caused by adrenergic and serotoninergic transmissions appearto arise (the latter intermediary may also act through othermechanisms). The correctness of this hypothesis was demonstrated byclinical research.

The first clinical pharmacological investigation consisted of exploringthe cerebral haemodynamics of migraine patients by a non-invasivemethod, through recording the pulsatility of the cerebral arteries. Thegraphs plotted showed permanent anomalies relative to a normal controlpatient between attacks, thus enabling the migraine patient to bedefined objectively. Graphs were thus plotted after the benzamideaccording to the invention had been absorbed by migraine patients.

In a treatment by intramuscular injection of a single 100 mg dose of thebenzamide, the graph moves towards normalisation in 2 hours. This ismaintained under treatment with repeated doses (150 mg/day) given orallyfor 3 weeks.

Once the action of the benzamide according to the invention incorrecting anomalies in the cerebral haemodynamics of migraine sufferershad been demonstrated, clinical investigations were developedcomprising:

(1) A comparative study, by a crossed double blind method, the referenceproduct being oxetorone, which is medically known, applied to migraine.The study covered 63 migraine patients, the two treatments being appliedfor 30 days with an adequate interruption between sequences. The dose ofbenzamide was 150 mg per day, and that of oxetorone 120 mg, asrecommended by the literature. Analysis of the results, allowing bothfor therapeutic effectiveness and tolerance of the treatment, indicatesthat the benzamide according to the invention is statistically superiorto oxetorone (P<0.05).

(2) A comparative study with Pizotifene, an anti-histamine andantiserotonin compound which is also used in the basic treatment formigraine.

The study covered 17 patients suffering true attacks of migraine ofregular frequency, which thus enabled the effectiveness of the treatmentto be assessed from the number and intensity of attacks during a periodof one month.

The benzamide according to the invention was applied orally in a dose of150 mg per day, in three times. The Pizotifene was also administeredorally, with the progressive dosage recommended for the product (0.73mg×1 for 3 days-0.73 mg×2 for 3 days-0.73 mg×3 for 24 days).

The patients were distributed at random between the treatments.

Analysis of the results confirms the action of the benzamide accordingto the invention, which is shown to be more effective than the secondreference compound (P#0.02).

(3) An open investigation covering 80 patients, who were followed inout-patient treatment with 150 mg of benzamide per day, given orally in3 doses:

79% success was recorded, and in particularly severe cases of"accompanied" migraines the remission transformed the social life of thepatient. General tolerance of the treatment was very satisfactory.

In conclusion, the benzamide according to the invention has atherapeutic importance which is demonstrated in the basic treatment ofmigraine.

We claim:
 1. As a new product, N-(1-allyl-2-pyrrolidinyl-methyl)2-methoxy-4-amino-5-methylsulfamoyl benzamide, quaternary ammonium salts thereof, N-oxides thereof, optical isomers thereof and their pharmacologically acceptable acid addition salts. 